Neurosarcoidosis and the complexity in its differential diagnoses: A review

Innovations in Clinical Neuroscience

Volumn 9, Issue 4, 2012, Pages 10-16

  Spiegel, David R ^a   Morris, Kristyn ^a   Rayamajhi, Ubha ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

First episode psychosis; Interleukin 6; Neurosarcoidosis

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; KYNURENIC ACID; METHOTREXATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLANZAPINE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

AUDITORY HALLUCINATION; BIOPSY; BIPOLAR DISORDER; CELLULAR IMMUNITY; CEREBROSPINAL FLUID CIRCULATION DISORDER; CLINICAL FEATURE; CYTOKINE RELEASE; DELUSION; DIFFERENTIAL DIAGNOSIS; DRUG DOSE REDUCTION; FAMILY HISTORY; HELPER CELL; HUMAN; HYPERCALCEMIA; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LOADING DRUG DOSE; PSYCHOSIS; REMISSION; REVIEW; SARCOIDOSIS; SCHIZOPHRENIA; SEIZURE; TREATMENT DURATION; VISUAL HALLUCINATION;

EID: 84862017421     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Ligon CB, Judson MA. Impact of systemic corticosteroids on healthcare utilization in patients with sarcoidosis. Am J Med Sci. 2011;341(3):196-201.
2. Ahn SW, Kim KT, Youn YC, et al. Isolated spinal cord neurosarcoidosis diagnosed by cord biopsy and thalidomide trial. J Korean Med Sci. 2011;26(1):154-157.
3. Hamzeh N. Sarcoidosis. Med Clin North Am. 2011;95(6):1223-1234.
4. Joseph FG, Scolding NJ. Sarcoidosis of the nervous system. Pract Neurol. 2007;7(4):234-244.
5. Spiegel DR, Thomas CS, Shah P, et al. A possible case of mixed mania due to neurosarcoidosis treated successfully with methylprednisolone and ziprasidone: another example of frontal-subcortical disinhibition? Gen Hosp Psychiatry. 2010;32(3):342.e1-3.
6. Duwe BV, Turetsky BI. Misdiagnosis of schizophrenia in a patient with psychotic symptoms. Neuropsychiatry Neuropsychol Behav Neurol. 2002;15(4):252-260.
7. Vanasse A, Courteau J, Fleury MJ, et al. Treatment prevalence and incidence of schizophrenia in quebec using a population health services perspective: different algorithms, different estimates. Soc Psychiatry Epidemiol. 2011 Mar 29. [Epub ahead of print]
8. Westhout FD, Linskey ME. Obstructive hydrocephalus and progressive psychosis: rare presentations of neurosarcoidosis. Surgical Neurology. 2008:69(3):288-292.
9. Hoitsma E, Drent M, Sharma OP. A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century. Curr Opin Pulm Med. 2010;16(5):472-479.
10. Ginat DT, Dhillon G, Almast J. Magnetic resonance imaging of neurosarcoidosis. J Clin Imaging Sci. 2011;1:15. Epub 2011 Feb 11
11. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis-diagnosis and management. QJM. 1999;92(2):103-117.
12. Terushkin V, Stern BJ, Judson MA, et al. Neurosarcoidosis: presentations and management. Neurologist. 2010;16(1):2-15.
13. Shah R, Roberson GH, Curé JK. Correlation of MR imaging findings and clinical manifestations in neurosarcoidosis. AJNR Am J Neuroradiol. 2009;30(5):953-961.
14. Gullapalli D, Phillips LH. Neurologic manifestations of sarcoidosis. Neurology Clinics. 2002;20(1):59-83.
15. Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM. 2009;102(7):449-460.
16. Hoitsma E, Faber CG, Drent M et al. Neurosarcoidosis: a clinical dilemma. Lancet Neurol. 2004;3(7):397-407.
17. Gullapalli D, Phillips LH. Neurosarcoidosis. Curr Neurol Neurosci Rep. 2004;4(6):441-447.
18. Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry. 2009;80(3):297-304.
19. Gandelman-Marton R, Theitler J. When should a sleep-deprived EEG be performed following a presumed first seizure in adults? Acta Neurol Scand. 2011;124(3):202-205.
20. Ackermann D. Hypercalcemia in sarcoidosis-case report, prevalence, pathophysiology and therapeutic options. Ther Umsch. 2007;64(5):281-286.
21. Chiba Y, Satoh K, Ueda S, et al. Marked improvement of psychiatric symptoms after parathyroidectomy in elderly primary hyperparathyroidism. Endocr J. 2007;54(3):379-383.
22. Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12:233-239.
23. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state:" a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.
24. Allen RK, Sellars RE, Sandstrom PA. A prospective study of 32 patients with neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(2):118-125.
25. De Mulder D, Vandenberghe J. Neurosarcoidosis as a cause of manic psychosis. Tijdschr Psychiatr. 2008;50(11):741-745.
26. O'Brien GM, Baughman RP, Broderick JP, et al. Paranoid psychosis due to neurosarcoidosis. Sarcoidosis. 1994;11(1):34-36.
27. Bona JR, Fackler SM, Fendley MJ, et al. Neurosarcoidosis as a cause of refractory psychosis: a complicated case report. Am J Psychiatry. 1998;155(8):1106-1108.
28. Bourgeois JA, Maddock RJ, Rogers L, et al. Neurosarcoidosis and delirium. Psychosomatics. 2005;46(2):148-150.
29. Popli A P. Risperidone for the treatment of psychosis associated with neurosarcoidosis. J Clin Psychopharmacol. 1997;17(2):132-133.
30. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther. 1972;13(5):694-698. [No authors listed]
31. Riedel M, Spellmann I, Schwarz MJ et al. Decreased T cellular immune response in schizophrenic patients. J Psychiatr Res. 2007;41(1-2):3-7.
32. Gerke AK, Hunninghake G. The immunology of sarcoidosis. Clin Chest Med. 2008:29(3):379-390.
33. Janssen DG, Caniato RN, Verster JC, et al. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol. 2010;25(3):201-215.
34. Müller N, Schwarz M. Immune System and schizophrenia. Curr Immunol Rev. 2010;6(3):213-220.
35. Muller N, Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res. 2006;10(2):131-148.
36. Johnstone EC, Macmillan JF, Crow TJ. The occurrence of organic disease of possible or probable etiological significance in a population of 268 cases of first episode schizophrenia. Psychol Med. 1987;17(2):371-379.
37. Charles J, Miller G, Ng A. Management of psychosis in Australian general practice. Aust Fam Physician. 2006;35(3):88-89.
38. Boter H, Peuskens J, Libiger J, et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009;115(2-3):97-103.
39. Schennach-Wolff R, Jäger M, Mayr A, et al. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients-Is it all about early response? European Neuropsychopharmacology. 2011;21(5):370-378.
40. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1885.
41. Jarvis GE, Toniolo I, Ryder AG, et al. High rates of psychosis for black inpatients in Padua and Montreal: different contexts, similar findings. Soc Psychiatry Psychiatr Epidemiol. 2011;46(3):247-253.
42. Smith JK, Matheus MG, Castillo M. Imaging manifestations of neurosarcoidosis. AJR Am J Roentgenol. 2004;182(2):289-295.
43. Zuniga G, Ropper AH, Frank J. Sarcoid peripheral neuropathy. Neurology. 1991;41(10):1558-1561.
44. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153-2165.